...BioCentury VP and Editor in Chief Simone Fishburn, Concerto HealthAI...
...questions, we can answer them effectively." Karen Tkach Tuzman Concerto HealthAI Biomatics...

...the new study’s experimental group. The analysis is blinded to the patients’ outcomes. In contrast, Concerto HealthAI...
...from more than two years ago is irrelevant,” said Edward Stepanski, SVP and COO of Concerto HealthAI...
...quality and in reporting of endpoints and covariates could confound analyses. CEO Jeff Elton said Concerto HealthAI...

...the Winship Cancer Institute of Emory University, as well as authors from FDA, ASCO and Concerto HealthAI...
...Oaks, Calif. BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160), Beijing, China Clinical Research Alliance, New Hyde Park, N.Y. Concerto HealthAI...
...Belgium Targets Btk - Bruton's tyrosine kinase Allison Johnson, Staff Writer zanubrutinib (BGB-3111) American Society of Clinical Oncology BeiGene Ltd. Concerto HealthAI Emory...

...not disclosed. The first outcomes research data are expected in early 2020. Shannon Lehnbeuter, Staff Writer Pfizer Inc. AI Concerto HealthAI real-world...

...Oncology (ASCO) has expanded its real-world data collaboration with FDA to include data services companies Concerto HealthAI...
...10,000 de-identified patient records from cancer patients treated with checkpoint inhibitors. In the expanded partnership, Concerto HealthAI...
...Society of Clinical Oncology, Alexandria, Va. U.S. Food and Drug Administration (FDA), Silver Spring, Md. Concerto HealthAI...